After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...
The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with ...
The brain-computer interface technology personalizes therapy based on an individual’s brain activity.
For the one million people diagnosed with Parkinson's disease in the United States, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug ...
The company's adaptive deep brain stimulation technology for Parkinson's disease therapy is expected to be available ...
T here is still no cure for Parkinson’s disease, but the U.S. Food and Drug Administration (FDA) approved a new deep brain ...
The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.
The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...
(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.
The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy ...